CAMBRIDGE, Mass. and NORTH CHICAGO, Ill. – June 16, 2014 – Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE:ABBV) announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular  interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). 

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.

PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.

NORTH CHICAGO, Ill., June 10, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35^th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time.

NORTH CHICAGO, Ill., June 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:30 a.m. Central time.

-- €85 million investment creates greater manufacturing capacity to deliver new medicines for patients

NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of 84 percent, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States. These results were presented at the 50^th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 3 in Chicago.

NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme. Specifically, one patient experienced a complete response (CR) and three patients experienced partial responses (PR) as measured with the Revised Assessment in Neuro-Oncology (RANO) criteria. These results were presented for the first time at the 50^th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 3 in Chicago.

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time.

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA^® (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical program is in Phase III development. HUMIRA is not currently approved to treat any form of uveitis.